Atlas Trials

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Clinical trial NCT03580564 · COMPLETED

Trial details

NCT number
NCT03580564
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Classical Hodgkin Lymphoma
Start date
2018-08-01
Primary completion
2020-08-22
Enrollment
109

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.